Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

WH, Polonsky; F, Giorgino; J, Rosenstock; K, Whitmire; E, Lew; M, Coudert; A, Alvarez; C, Nicholls; RJ, McCrimmon

doi:10.1111/dom.14822

Public

Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

Shared by NobleBlocks on Aug 23, 2022 • 12:00 AM UTC

Authors:

Polonsky WH

Giorgino F

Rosenstock J

Abstract

<h4>Aim</h4>To assess patient-reported outcomes (PROs) in the SoliMix trial, which compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D).<h4>Materials and methods</h4>SoliMix (EudraCT: 2017-003370-13), a 26-week, open-label study, randomized (1:1) 887 adu...

Subject

Type 2 diabetes

Basal Insulin

Patient-reported Outcomes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!